Perrigo: This 11% Yielder Should Cut The Dividend

Perrigo's 10.9% dividend yield is not covered by free cash flow, and the stock is viewed as vulnerable to a dividend cut unless additional divestitures occur. The company’s distressed balance sheet and high leverage remain key concerns, while recent asset sales such as Dermacosmetics provide only short-term relief and reduce margins. The article reinforces a cautious near-term outlook for PRGO despite some portfolio rationalization.

Analysis

PRGO looks like a classic balance-sheet repair story where the equity is effectively a residual claim on asset sales rather than on durable operating cash generation. That creates a negative convexity setup: every divestiture may buy time, but it also shrinks the earnings base and makes the next funding gap harder to bridge unless leverage falls materially faster than EBITDA.

The second-order loser is the ecosystem around the company, not just shareholders. Suppliers and distributors tend to price in distress early, which can pressure working capital terms and promotional spend; that can further weaken organic momentum and force management into a self-reinforcing cycle of cutting investment to defend liquidity. Competitors with cleaner balance sheets can exploit this by locking in shelf space, negotiating better terms, and taking share while PRGO is distracted by capital structure management.

The catalyst path is asymmetric over the next 1-3 quarters: the market will likely trade the stock on any sign of a dividend reset, covenant headroom deterioration, or another non-core sale. A near-term relief rally is possible if management announces incremental asset monetization or financing, but that likely just converts equity value into reduced bankruptcy probability rather than creating real upside unless the payout is cut and leverage falls decisively.

Consensus may be underestimating how quickly a dividend cut can improve survivability while still hurting the stock. If management acts early, the initial reaction is usually negative, but the medium-term read-through is better for creditors and possibly better for the equity than a delayed, forced cut after another quarter of cash leakage. The key question is not whether the dividend is unsustainable; it is whether the company chooses a controlled repair process before the market forces one.

Key Decisions for Investors

• Short PRGO on strength over the next 1-4 weeks; use any rally tied to asset-sale headlines as an entry point. Risk/reward is favorable if the market begins pricing a dividend reset or leverage-driven equity dilution within 1-3 quarters.
• Buy PRGO puts 3-6 months out, targeting strikes below the current spot where dividend-cut optionality is not yet fully priced. This is a cleaner expression than stock shorting if borrow tightens or the name gaps on restructuring news.
• Pair trade: long a higher-quality consumer staples/pharma peer with steadier cash generation, short PRGO. The relative value thesis is that capital returns should migrate toward balance-sheet-safe names if the market rotates away from yield traps.
• If already long PRGO for yield, reduce exposure ahead of the next earnings/update window; the best-case scenario is likely capital preservation, not total return outperformance, over the next 6-12 months.
• Set a catalyst watch for any announced divestiture or refinancing package. If accompanied by no dividend reset, that can be a short-covering event, but treat it as an opportunity to fade unless leverage metrics clearly improve.